Literature DB >> 27171547

Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State.

Melissa P Wasserstein1, Mary Andriola2, Georgianne Arnold3,4, Alan Aron5,6, Patricia Duffner7, Richard W Erbe8, Maria L Escolar3,4, Lissette Estrella9, Patricia Galvin-Parton10, Alejandro Iglesias11, Denise M Kay12, David F Kronn13, Joanne Kurtzberg14,15, Jennifer M Kwon16,17,18, Thomas J Langan19,20, Paul A Levy21, Thomas P Naidich22,23,5, Joseph J Orsini12, Joan E Pellegrino24, James M Provenzale25, David A Wenger26, Michele Caggana12.   

Abstract

BACKGROUND: Early infantile Krabbe disease is rapidly fatal, but hematopoietic stem cell transplantation (HSCT) may improve outcomes if performed soon after birth. New York State began screening all newborns for Krabbe disease in 2006.
METHODS: Infants with abnormal newborn screen results for Krabbe disease were referred to specialty-care centers. Newborns found to be at high risk for Krabbe disease underwent a neurodiagnostic battery to determine the need for emergent HSCT.
RESULTS: Almost 2 million infants were screened. Five infants were diagnosed with early infantile Krabbe disease. Three died, two from HSCT-related complications and one from untreated disease. Two children who received HSCT have moderate to severe developmental delays. Forty-six currently asymptomatic children are considered to be at moderate or high risk for development of later-onset Krabbe disease.
CONCLUSIONS: These results show significant HSCT-associated morbidity and mortality in early infantile Krabbe disease and raise questions about its efficacy when performed in newborns diagnosed through newborn screening. The unanticipated identification of "at risk" children introduces unique ethical and medicolegal issues. New York's experience raises questions about the risks, benefits, and practicality of screening newborns for Krabbe disease. It is imperative that objective assessments be made on an ongoing basis as additional states begin screening for this disorder.Genet Med 18 12, 1235-1243.

Entities:  

Mesh:

Year:  2016        PMID: 27171547     DOI: 10.1038/gim.2016.35

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  30 in total

Review 1.  Newborn screening for Krabbe's disease.

Authors:  Joseph J Orsini; Carlos A Saavedra-Matiz; Michael H Gelb; Michele Caggana
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

2.  Evidence for improved survival in postsymptomatic stem cell-transplanted patients with Krabbe's disease.

Authors:  Thomas J Langan; Amy L Barcykowski; Jonathan Dare; Erin C Pannullo; Leah Muscarella; Randy L Carter
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 3.  Inborn errors of metabolism in the 21st century: past to present.

Authors:  Georgianne L Arnold
Journal:  Ann Transl Med       Date:  2018-12

Review 4.  Newborn screening and changing face of inborn errors of metabolism in the United States.

Authors:  Shibani Kanungo; Dilip R Patel; Mekala Neelakantan; Brinda Ryali
Journal:  Ann Transl Med       Date:  2018-12

Review 5.  Emptying the stores: lysosomal diseases and therapeutic strategies.

Authors:  Frances M Platt
Journal:  Nat Rev Drug Discov       Date:  2017-11-17       Impact factor: 84.694

6.  Long-Term Improvement of Neurological Signs and Metabolic Dysfunction in a Mouse Model of Krabbe's Disease after Global Gene Therapy.

Authors:  Michael S Marshall; Yazan Issa; Benas Jakubauskas; Monika Stoskute; Vince Elackattu; Jeffrey N Marshall; Wil Bogue; Duc Nguyen; Zane Hauck; Emily Rue; Subha Karumuthil-Melethil; Violeta Zaric; Maarten Bosland; Richard B van Breemen; Maria I Givogri; Steven J Gray; Stephen J Crocker; Ernesto R Bongarzone
Journal:  Mol Ther       Date:  2018-01-17       Impact factor: 11.454

Review 7.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

8.  Elevated Leukodystrophy Incidence Predicted From Genomics Databases.

Authors:  Haille E Soderholm; Alexander B Chapin; Pinar Bayrak-Toydemir; Joshua L Bonkowsky
Journal:  Pediatr Neurol       Date:  2020-06-17       Impact factor: 3.372

9.  Screening of Newborns for Disorders with High Benefit-Risk Ratios Should Be Mandatory.

Authors:  Nicole Kelly; Dalia Chehayeb Makarem; Melissa P Wasserstein
Journal:  J Law Med Ethics       Date:  2016-06       Impact factor: 1.718

Review 10.  Lysosomal storage diseases.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.